Clinical cardiology could benefit from greater insights into the pathology of cardiomyocytes in inherited cardiac disease. However, the availability of diseased cardiomyocytes is limited by the scarcity of biopsies from patients and the amount of tissue they yield. The advent of induced pluripotent stem cells, through which somatic cells can be genetically reprogrammed into stem cells able to differentiate to cardiomyocytes, now presents opportunities for solving this. However, a remaining issue is the extent to which the phenotype in these cells actually resembles that of cardiomyocytes in the heart itself. Here, we used reprogramming to investigate a cardiac overlap syndrome caused by a mutation in SCN5A, the sodium channel gene. Patients with this mutation (1795insD) can display symptoms of both long-QT syndrome type 3 and Brugada syndrome. We first derived induced pluripotent stem cells from mice with the corresponding SCN5A mutation. The derivative cardiomyocytes had electrophysiological properties similar to primary cardiomyocytes from the same heterozygous mutant mouse and from the embryonic stem cells used to generate it. The mutation resulted in a reduced Na ϩ current density (Brugada syndrome) and prolonged action potential (long-QT syndrome type 3), demonstrating that stem cell-derived cardiomyocytes could recapitulate the functional characteristics responsible for the observed multiple phenotypes. We then derived induced pluripotent stem cells from a patient with the SCN5A 1795insD/ϩ mutation. The cardiomyocytes derived from these cells showed changes in the Na ϩ channel biophysical properties similar to those in the mouse cardiomyocytes, demonstrating that human induced pluripotent stem cells could also model the pathognomonic features of the overlap syndrome. This model offers new opportunities for identifying drug effectiveness and sensitivities of clinical relevance. See p 3079.
Association Between Family History and Coronary Heart Disease Death Across Long-Term Follow-Up in Men: The Cooper Center Longitudinal Study
Sustained exposure to the genetic factors involved in a family history of premature coronary heart disease (CHD) can be expected to result in a significant accumulation of CHD risk over a patient's lifetime. Although a family history of CHD is a well-described short-term risk factor, data are sparse on the association between family history and long-term risk. Accordingly, current prevention guidelines recommend the use of short-term risk estimation to guide treatment decisions such as statin therapy. In this study involving 49 255 men from the Cooper Center Longitudinal Study and more than 800 000 person-years of follow-up, we investigated the association between premature family history and CHD mortality. After adjusting for traditional risk factors, we observed a persistent association between premature family history and both CHD and cardiovascular disease mortality across short-term (0 -10 years), intermediate-term (Ͼ10 -20 years), and long-term (Ͼ20 years) follow-up. We also observed that premature family history was associated with a 50% increase in the lifetime risk for both cardiovascular disease and CHD mortality, approaching that of a major CHD risk factor. We believe that these findings are useful for clinicians and provide a broader context with which to consider the effects of premature family history on the lifetime risk of CHD. See p 3092.
Persistent Renal Damage After Contrast-Induced Acute Kidney Injury: Incidence, Evolution, Risk Factors, and Prognosis
Acute kidney injury after exposure to iodinated contrast media (CI-AKI) increases morbidity, early mortality, and hospital stay. Even though there is evidence for a cause-and-effect relationship between CI-AKI and long-term occurrence of adverse cardiovascular events, the longterm evolution of renal function after an episode of CI-AKI is less clear. The aim of this prospective cohort study was to evaluate the incidence, risk factors, and prognostic implications of persistent renal damage (RD) in patients with preexistent moderate-to-severe renal dysfunction who developed CI-AKI. In patients who developed CI-AKI, persistent RD was defined as a relative decrease of creatinine clearance of Ն25% over baseline at 3 months. Patients whose creatinine clearance returned to baseline (or nearly) were classified as transient RD. Patients were followed up for up to 3.8 years for subsequent cardiovascular and renal outcomes. Persistent RD 3 months after CI-AKI was independently associated with a 2.3-fold increase in the risk of death and a 2.5-fold increase in the risk of combined clinical end points (mortality, dialysis, and/or major cardiovascular events); transient RD was independently associated with a 1.3-fold increase in the risk of death and a 1.6-fold increase in the risk of combined end points in comparison with patients without CI-AKI. The results of the present article confirm that, in patients with moderate-to-severe renal dysfunction, CI-AKI is not simply a "transient, benign creatininopathy," but rather a direct cause of worsening chronic renal function and identifies a subgroup of patients with an increased risk of cardiovascular events. See p 3099.
Association Between Sodium Intake and Change in Uric Acid, Urine Albumin Excretion, and the Risk of Developing Hypertension
Although a short-term sodium load does not usually raise blood pressure, a long-term high sodium intake is associated with increases in blood pressure. The reasons for this are unclear. Our study suggests that a high-sodium diet over the long term may lead to endothelial dysfunction and vascular damage, generating a biological state in which continuance of the highsodium diet may produce hypertension (a sodium amplification loop). See p 3108.
Novel Single-Chain Antibody-Targeted Microbubbles for Molecular Ultrasound Imaging of Thrombosis: Validation of a Unique Noninvasive Method for Rapid and Sensitive Detection of Thrombi and Monitoring of Success or Failure of Thrombolysis in Mice
Clinical ultrasound is widely used for real-time cardiovascular imaging of anatomic structures and functional evaluation. Contrastenhancing microbubbles are used in the clinic to support visualization of cardiac structures and myocardial perfusion or to diagnose patent foramen ovale. This study substantially advances the use of microbubbles for a molecular imaging approach by their targeting, and it provides a clinically highly relevant perspective of the detection of activated platelets and thrombi in ultrasound. Successful high-resolution imaging of thrombi induced in the carotid artery of mice and monitoring of the reduction of thrombus size on pharmacological thrombolysis were achieved by coupling microbubbles with a single-chain antibody that binds to a ligand-induced binding site. The latter is exposed only on platelet receptor glycoprotein IIb/IIIa in its activated state, providing a unique target specificity, as shown with our targeted microbubbles in both mice and humans. Several potential clinical applications of this technology can be anticipated such as early detection of unstable carotid artery plaques characterized by microthrombi, visualization of thrombi in cardiac chambers, particularly in the left atrial appendage, and diagnosis of thrombi causing myocardial infarction. Furthermore, the potential to directly monitor and assess pharmacological thrombolysis in real time could provide clinically highly relevant guidance for consequent treatment. Because ultrasound is cost-effective, portable, and widely available, its application for molecular imaging using microbubbles targeted to activated platelets may provide a unique approach for the development of a rapid and noninvasive diagnosis of thrombotic diseases and for monitoring of the success or failure of thrombolysis. See p 3117.
Echocardiography Screening for Rheumatic Heart Disease in Ugandan Schoolchildren
The World Health Organization has made the fight against noncommunicable disease, including acquired cardiovascular disease, a top priority for the next decade. The World Heart Federation has made "eliminating rheumatic fever and minimizing the burden of rheumatic heart disease" 1 of its 6 priorities for the coming 5 years. Rheumatic heart disease affects nearly 20 million people worldwide. It disproportionately affects the developing world, causing death and disability in the prime of life. Widespread screening for rheumatic heart disease based on standardized published echocardiographybased guidelines in the most endemic regions of the developing world will be a critical component of the World Heart Federation effort. Echocardiography allows earlier detection, when penicillin remains an effective and affordable prophylaxis against progressive valvular disease. Our article provides the largest study on prevalence data for echocardiography-based screening for rheumatic heart disease in sub-Saharan Africa and is the first to use published echocardiography-based guidelines in this region. Our results also help to define choices about age, socioeconomic status, and diagnostic protocol that will influence the development and implementation of future screening programs. Furthermore, we emphasize the need for longitudinal follow-up to validate current definitions of subclinical rheumatic heart disease. As echocardiography-based screening protocols increase in prominence and are redefined, these data call for increased awareness and focus on the world's most prevalent heart disease. See p 3127.
Long-Term Outcome of Aortic Dissection With Patent False Lumen: Predictive Role of Entry Tear Size and Location
Persistent patent false lumen in descending aorta after acute aortic dissection is common in type A and type B dissections and has been associated with poor prognosis. However, to date, no study has shown that elective surgical or endovascular treatment in subacute phase of aortic dissection reduces mortality. Therefore, identification of clinical and imaging predictors of poor prognosis seems mandatory. We studied 184 patients, 108 surgically treated type A and 76 medically treated type B dissections, discharged with patent false lumen in descending aorta. Transesophageal echocardiography and computed tomography were performed to assess several imaging variables. During follow-up (median, 6.4 years) 49 patients died; 31 died suddenly, and 35 underwent surgical/endovascular treatment. Survival free from complications at 3, 5, and 10 years was 0.90 (95% CI, 0.84 -0.94), 0. 81 (95% CI, 0.75-0.87), and 0.46 (95% CI, 0.36 -0.55), respectively. Marfan syndrome was the only clinical variable associated with mortality. Concerning imaging variables, patients with complications had a larger baseline maximum diameter in descending aorta and a larger proximal entry tear. Patients with entry tear size Ն10 mm presented a high incidence of aortic-related events (hazard ratioϭ5.8 (3.3-10; PϽ0.001). Our findings may help to identify patients at higher risk of complications by imaging techniques performed in subacute phase of aortic dissection. Patients with dilated aorta and large entry tears may benefit from more aggressive surveillance and treatment, including surgical or endovascular therapy, to improve their long-term prognosis. See p 3133.
Endothelial Cell-Specific FGD5 Involvement in Vascular Pruning Defines Neovessel Fate in Mice
The capacity of endothelial cells in the vasculature to regenerate in human adults depends largely on the same molecular pathways that regulate the process of angiogenesis during embryonic development. Growth of neovessel not only is determined by the availability of growth factors such as vascular endothelial growth factor-A but also depends on the ability of the neovascular structure to maintain stability while excess vessel structures are actively removed by a biological mechanism called vascular pruning. In this article, a novel factor named FYVE, RhoGEF, and PH domain-containing 5 (FGD5) was discovered to be involved in active regulation of this pruning process. A better understanding of the molecular pathways that govern vascular pruning could benefit patient treatment in therapies in which stimulation of vascular growth is desired and in which this type of regulation should be adapted. See p 3142.
C1q/Tumor Necrosis Factor-Related Protein-3, a Newly Identified Adipokine, Is a Novel Antiapoptotic, Proangiogenic, and Cardioprotective Molecule in the Ischemic Mouse Heart
Cardiovascular disease remains a leading cause of mortality worldwide. Although improved reperfusion strategies have led to declined death rates after acute myocardial infarction, both the incidence and prevalence of post-myocardial infarction heart failure have continually increased in recent years. As a result of the increased incidence of diabetes mellitus and its association with heart failure, there is now great interest in elucidating the underlying molecular mechanisms linking these pathologies. Considerable evidence exists that the majority of adipokines (including tumor necrosis factor [TNF]-␣, leptin, plasminogen activator inhibitor type 1, transforming growth factor-␤, and resistin) adversely regulate myocardial metabolism, cardiomyocyte hypertrophy, extracellular matrix structure and composition, and cell death. The present study demonstrated that C1q/TNF-related protein-3 (CTRP3), a key member of a newly identified adipokine family, exerts cardiac actions opposing the majority of other adipokines and is a novel and potent cardioprotective molecule. Expression and production of CTRP3 are significantly reduced after myocardial infarction, and replenishment of CTRP3 protects the heart by attenuating postischemic pathologic remodeling and promoting cardiomyocyte-endothelial cell communication. These results suggest that the balance between cardioprotective and cardio-harmful cytokines tilts during pathological conditions such as heart failure. Interventions restoring the balance may represent a novel therapeutic strategy in the treatment of cardiovascular diseases, particularly in those patients with diabetes mellitus. See p 3159.
Impaired Autophagosome Clearance Contributes to Cardiomyocyte Death in Ischemia/Reperfusion Injury
In myocardial infarction resulting from coronary occlusion, contemporary therapy is focused on expedient reperfusion to prevent loss of myocardium. Despite reperfusion and often as a result of reperfusion injury, there is ongoing cardiomyocyte cell death, which can be targeted therapeutically to maximize myocardial salvage. Autophagy is an evolutionarily conserved lysosomal pathway to break down damaged cellular constituents, to provide nutrients, and to facilitate cell survival. Autophagy has also been implicated as a mechanism for programmed cell death. In cardiac ischemia/reperfusion injury, autophagy is upregulated, and previous studies have suggested that it plays a dichotomous role in facilitating cell survival during ischemia but provoking cell death during reperfusion. To examine the hypothesis that autophagy is upregulated in reperfusion injury but impaired, thus preventing its prosurvival function, we have carefully examined flux through the autophagy pathway in cardiomyocytes subjected to ischemia and reperfusion. Our results demonstrate that autophagosomes accumulate during reperfusion injury after myocardial ischemia, suggesting impaired autophagosome processing. This accumulation of autophagosomes, presumably with the deleterious cargo that is not degraded, is associated with an increased prevalence of reactive oxygen species and mitochondrial permeabilization, resulting in necrotic cardiomyocyte death. The underlying mechanism for the impairment in autophagosome processing appears to be a reperfusion-induced decline in lysosome-associated membrane protein-2 levels, a protein critical for autophagosome-lysosome fusion, and an increase in the abundance of BECLIN-1. Restoring lysosome-associated membrane protein-2 levels and knocking down BECLIN-1 restore autophagosome processing with the attenuation of cell death. Thus, facilitating autophagy with enhanced flux through the autophagy pathway is a promising strategy to achieve myocardial salvage in ischemia/reperfusion injury. See p 3170.
The United States Registry for Fibromuscular Dysplasia: Results in the First 447 Patients
Fibromuscular dysplasia (FMD) is a nonatherosclerotic, noninflammatory vascular disease that primarily affects women in the prime of their life. There is an average delay of 5 years from the onset of symptoms until the diagnosis of FMD is made. FMD most commonly affects the renal, carotid, and vertebral arteries but may occur in virtually every artery of the body. Multivessel involvement is common. The most common clinical manifestations of FMD are hypertension, headaches, pulsatile tinnitus, and dizziness. However, 1 in 5 patients experience a dissection, and 17% have one or more aneurysms. A cerebrovascular event including transient ischemic attack, stroke, and/or amaurosis fugax occur in 1 of every 4 patients with FMD. The presence of a carotid bruit in a patient under 60 or an epigastric bruit in a patient with hypertension should alert the clinician to the possible diagnosis of FMD. Earlier diagnosis may prevent the consequences of poorly controlled hypertension, and allow for the identification of aneurysms and dissections and their appropriate treatment. See p 3182.
Use of an Intrapericardial, Continuous-Flow, Centrifugal Pump in Patients Awaiting Heart Transplantation
This study investigated a small, intrapericardially positioned, continuous-flow centrifugal pump, the HeartWare ventricular assist device, as a bridge to heart transplantation. The course of 140 investigational pump patients was compared with that of 499 patients implanted contemporaneously as a bridge to transplantation with commercially available ventricular assist devices and enrolled in a national registry. Perioperative mortality for the investigational pump group was 1%, and Kaplan-Meier estimated survival at 1 year was 90%. The primary outcome, defined as survival on the originally implanted device, transplantation, or explantation for ventricular recovery at 180 days, occurred in 92.0% of investigational pump patients and 90.1% of controls, establishing the noninferiority of the investigational pump. At 6 months, 6-minute walk test distance improved by 152 m, and both disease-specific and global qualityof-life scores improved substantially. The adverse event profile with the investigational pump was notable for relatively low rates of gastrointestinal bleeding and bleeding requiring surgery, with other adverse event rates similar to those reported previously for continuous-flow pumps in bridge-to-transplantation trials. Qualityof-life and functional capacity improvements were much larger than seen with any drug or device therapy for advanced heart failure and similar to those obtained with cardiac transplantation. This study demonstrates the excellent outcomes that are now achievable with the present generation of small, continuous-flow pumps. See p 3191.
Antiplatelet Drug Response Status Does Not Predict Recurrent Ischemic Events in Stable Cardiovascular Patients: Results of the Antiplatelet Drug Resistances and Ischemic Events Study
Poor biological response to antiplatelet drugs has repeatedly been associated with recurrence of ischemic events in cardiovascular patients. However, most studies involved coronary artery disease patients with recent vessel injury shortly after the initiation of antiplatelet therapy. The present study provides outcome data on 771 stable cardiovascular patients who were treated with aspirin and/or clopidogrel and were followed up for 3 years and in whom antiplatelet drug responsiveness was characterized twice with various platelet function assays at least 1 month after their last acute ischemic event. Major adverse cardiovascular events (MACEs) occurred in 16% of the patients. Hypertension, smoking, older age, and elevated low-density lipoprotein cholesterol were predictive of MACE recurrence, but neither the results of the specific assays (serum thromboxane B2 for the response to aspirin and vasodilator phosphoprotein platelet reactivity index for the response to clopidogrel) nor those of the aggregation-based platelet function assays added any incremental predictive value for the recurrence of MACEs. MACE-free survival was not significantly different for patients with only 1 good response (to either aspirin or clopidogrel; hazard ratio, 0.94; 95% confidence interval, 0.51-1.76) and for patients with a good response to both aspirin and clopidogrel (hazard ratio, 0.87; 95% confidence interval, 0.44 -1.69) compared with patients with poor responses to both drugs. These results contrast with studies of other populations, including acute patients and/or patients assessed for platelet reactivity Ͻ1 month after treatment initiation. The results of the Antiplatelet Drug Resistances and Ischemic Events (ADRIE) study do not support routine platelet function testing for MACE risk evaluation in stable cardiovascular outpatients. See p 3201.
